©2024 Stanford Medicine
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Not Recruiting
Trial ID: NCT01833039
Purpose
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell
Lymphoma (MCL) with early access to an investigational medication called ibrutinib
(PCI-32765) and to collect safety information about the drug.
Official Title
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Stanford Investigator(s)
Lauren Maeda
Clinical Associate Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or
refractory disease after prior therapy are eligible.
Exclusion Criteria:
- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are
not eligible.
- Patients previously treated with ibrutinib are not eligible.
- Patients enrolled in another interventional clinical study with therapeutic intent are
not eligible.
Intervention(s):
drug: Ibrutinib
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061